Kirsi Hämäläinen

1.4k total citations
32 papers, 1.0k citations indexed

About

Kirsi Hämäläinen is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Kirsi Hämäläinen has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Reproductive Medicine and 10 papers in Oncology. Recurrent topics in Kirsi Hämäläinen's work include Ovarian cancer diagnosis and treatment (11 papers), Angiogenesis and VEGF in Cancer (7 papers) and Proteoglycans and glycosaminoglycans research (5 papers). Kirsi Hämäläinen is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Angiogenesis and VEGF in Cancer (7 papers) and Proteoglycans and glycosaminoglycans research (5 papers). Kirsi Hämäläinen collaborates with scholars based in Finland, United Kingdom and Netherlands. Kirsi Hämäläinen's co-authors include Kirsi Rilla, Kirsi Kananen, Seppo Auriola, Arto Urtti, Kyösti Kontturi, Veli‐Matti Kosma, Maarit Anttila, Markku Tammi, Raija Tammi and Satu Tiainen and has published in prestigious journals such as PLoS ONE, International Journal of Cancer and European Journal of Cancer.

In The Last Decade

Kirsi Hämäläinen

31 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kirsi Hämäläinen Finland 17 468 294 211 147 141 32 1.0k
Karen D. Cowden Dahl United States 15 678 1.4× 277 0.9× 141 0.7× 120 0.8× 102 0.7× 26 1.1k
Doreen LePage United States 11 450 1.0× 291 1.0× 163 0.8× 65 0.4× 30 0.2× 24 888
Jung‐Joo Choi South Korea 24 830 1.8× 316 1.1× 386 1.8× 62 0.4× 180 1.3× 41 1.5k
Nadine Pavloff United States 10 592 1.3× 452 1.5× 143 0.7× 102 0.7× 23 0.2× 17 1.6k
Adam D. Steg United States 20 1.2k 2.6× 852 2.9× 94 0.4× 114 0.8× 197 1.4× 44 1.8k
Renee M. McGovern United States 22 693 1.5× 534 1.8× 111 0.5× 47 0.3× 31 0.2× 50 1.5k
Xuesong Yang China 20 715 1.5× 361 1.2× 308 1.5× 86 0.6× 65 0.5× 33 1.2k
I.-M. Shih United States 11 343 0.7× 182 0.6× 232 1.1× 79 0.5× 177 1.3× 15 768
Yasushi Saga Japan 22 670 1.4× 354 1.2× 200 0.9× 91 0.6× 273 1.9× 66 1.4k
Gustavo Linares‐Cruz France 13 934 2.0× 220 0.7× 210 1.0× 89 0.6× 14 0.1× 18 1.3k

Countries citing papers authored by Kirsi Hämäläinen

Since Specialization
Citations

This map shows the geographic impact of Kirsi Hämäläinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirsi Hämäläinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirsi Hämäläinen more than expected).

Fields of papers citing papers by Kirsi Hämäläinen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirsi Hämäläinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirsi Hämäläinen. The network helps show where Kirsi Hämäläinen may publish in the future.

Co-authorship network of co-authors of Kirsi Hämäläinen

This figure shows the co-authorship network connecting the top 25 collaborators of Kirsi Hämäläinen. A scholar is included among the top collaborators of Kirsi Hämäläinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirsi Hämäläinen. Kirsi Hämäläinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hämäläinen, Kirsi, Kirsi Rilla, Sanna Oikari, et al.. (2024). High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer. Cancers. 16(3). 634–634. 8 indexed citations
2.
Tiainen, Satu, Hanna Siiskonen, Maarit Ahtiainen, et al.. (2023). The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer. Breast Cancer Research and Treatment. 201(2). 183–192. 11 indexed citations
3.
Sallinen, Hanna, Kirsi Hämäläinen, Annukka M. Kivelä, et al.. (2020). High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer. PLoS ONE. 15(11). e0241484–e0241484. 11 indexed citations
4.
Tiainen, Satu, Kirsi Rilla, Kirsi Hämäläinen, Sanna Oikari, & Päivi Auvinen. (2020). The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. Breast Cancer Research and Treatment. 185(1). 63–72. 31 indexed citations
5.
Tiainen, Satu, Amro Masarwah, Sanna Oikari, et al.. (2019). Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis. Breast Cancer Research and Treatment. 179(3). 565–575. 34 indexed citations
6.
Anttila, Maarit, Suvi Rautiainen, Otso Arponen, et al.. (2019). Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression. PLoS ONE. 14(8). e0221340–e0221340. 14 indexed citations
7.
Tiainen, Satu, Sanna Oikari, Markku Tammi, et al.. (2016). High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome. Breast Cancer Research and Treatment. 160(2). 237–247. 16 indexed citations
8.
Libard, Sylwia, Svetlana N. Popova, Rose‐Marie Amini, et al.. (2014). Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade. PLoS ONE. 9(9). e108861–e108861. 41 indexed citations
9.
Sallinen, Hanna, J. Koponen, Maarit Anttila, et al.. (2013). Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer. PubMed. 24(1). 29–37. 9 indexed citations
10.
Anttila, Maarit, Hanna Sallinen, Svetlana Laidinen, et al.. (2012). Antiangiogenic gene therapy with soluble VEGF‐receptors ‐1, ‐2 and ‐3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. International Journal of Cancer. 131(10). 2394–2401. 16 indexed citations
11.
Sallinen, Hanna, Maarit Anttila, Olli Gröhn, et al.. (2010). Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. Cancer Gene Therapy. 18(2). 100–109. 13 indexed citations
12.
Nykopp, Timo K., Kirsi Rilla, Markku Tammi, et al.. (2010). Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma. BMC Cancer. 10(1). 512–512. 48 indexed citations
13.
Hämäläinen, Kirsi, Veli-Matti Kosma, Raija Tammi, et al.. (2009). Downregulated CD44 and hyaluronan expression in vulvar intraepithelial neoplasia and squamous cell carcinomas. Acta Obstetricia Et Gynecologica Scandinavica. 89(1). 108–119. 5 indexed citations
14.
Pukkila, Matti, Jukka Virtaniemi, Risto Pirinen, et al.. (2009). Reduced γ-Catenin Expression and Poor Survival in Oral Squamous Cell Carcinoma. Archives of Otolaryngology - Head and Neck Surgery. 135(10). 1035–1035. 13 indexed citations
15.
Tuhkanen, Hanna, Ylermi Soini, Veli‐Matti Kosma, et al.. (2009). Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer. 9(1). 289–289. 28 indexed citations
16.
Hämäläinen, Kirsi. (2008). Urheilija ja valmentaja urheilun maailmassa : eetokset, ihanteet ja kasvatus urheilijoiden tarinoissa. Jyväskylä University Digital Archive (University of Jyväskylä).
17.
Nowee, Marlies E., Josephine C. Dorsman, Jurgen M.J. Piek, et al.. (2007). HER‐2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Histopathology. 51(5). 666–673. 12 indexed citations
18.
Anttila, Maarit, et al.. (2007). Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer. European Journal of Cancer. 43(8). 1300–1307. 17 indexed citations
19.
Vanto, T., et al.. (2004). Comparison of Two Budesonide Dry Powder Inhalers in the Treatment of Asthma in Children. Journal of Aerosol Medicine. 17(1). 15–24. 23 indexed citations
20.
Hämäläinen, Kirsi, et al.. (2001). Assessment of the systemic effects of budesonide inhaled from Easyhaler®and from Turbuhaler®in healthy male volunteers. Respiratory Medicine. 95(11). 863–869. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen D. Cowden Dahl Breakdown of academic impact, for papers by Doreen LePage Breakdown of academic impact, for papers by Jung‐Joo Choi Breakdown of academic impact, for papers by Nadine Pavloff Breakdown of academic impact, for papers by Adam D. Steg Breakdown of academic impact, for papers by Renee M. McGovern Breakdown of academic impact, for papers by Xuesong Yang Breakdown of academic impact, for papers by I.-M. Shih Breakdown of academic impact, for papers by Yasushi Saga Breakdown of academic impact, for papers by Gustavo Linares‐Cruz
Rankless by CCL
2026